EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Nose-to-Brain Co-delivery of Temozolomide and Ganoderma lucidum Spore Oil in a Microemulsion for Enhanced Glioblastoma Therapy

Xiaoyuan Guo, Xingxing Jin, Zhibo Zhang, Hongmei Liu

ACS Omega · 19.11.2026

DOI: 10.1021/acsomega.6c07252 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Omega, online erschienen am 19.11.2026. Verfasst von Xiaoyuan Guo und 3 weiteren Autor:innen. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Nanjing Municipal Health Bureau, Zhongda Hospital Affiliated to Southeast University, Jiangsu Province High-Level Hospital Construction Funds.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Temozolomide (TMZ)-based chemotherapy for glioblastoma (GBM) is severely limited by the blood–brain barrier (BBB) and the highly immunosuppressive tumor microenvironment (TME). Ganoderma lucidum spore oil (GSO) has TME-remodeling capacity, but its efficient delivery to the brain remains challenging. Here, we developed a TMZ and GSO coloaded microemulsion (TMZ&GSO-MEs) optimized for intranasal nose-to-brain delivery. Using an “active ingredient-as-excipient” design, GSO partially replaced the conventional oil phase, resulting in a uniform nanoscale formulation (∼35 nm), high encapsulation efficiency (92.6%), and sustained release. TMZ&GSO-MEs significantly enhanced cellular uptake of both TMZ and GSO and exhibited superior antiproliferative activity in GL261 cells compared to free TMZ. In an orthotopic Luc-GL261 glioma model, intranasal administration of TMZ&GSO-MEs markedly suppressed tumor growth (inhibition rate 66.5%) and extended survival (25% of mice alive at day 60). Mechanistically, GSO reprogrammed the TME by increasing M1-type tumor-associated macrophages, CD8+ T cells, and activated dendritic cells, while decreasing M2-type macrophages and TGF-β1 and shifting serum cytokines toward a Th1-dominant profile. Notably, the formulation showed a favorable safety profile with no significant body weight loss or hepatorenal toxicity. Collectively, this nose-to-brain microemulsion integrates enhanced intracranial delivery, chemo-immunotherapeutic synergy, and reduced toxicity, offering a promising strategy for GBM therapy.

Förderung

  • Nanjing Municipal Health Bureau
  • Zhongda Hospital Affiliated to Southeast University, Jiangsu Province High-Level Hospital Construction Funds

Zitieren

APA

Guo, X., Jin, X., Zhang, Z., & Liu, H. (2026). Nose-to-Brain Co-delivery of Temozolomide and Ganoderma lucidum Spore Oil in a Microemulsion for Enhanced Glioblastoma Therapy. ACS Omega. https://doi.org/10.1021/acsomega.6c07252

Vancouver

Guo X, Jin X, Zhang Z, Liu H. Nose-to-Brain Co-delivery of Temozolomide and Ganoderma lucidum Spore Oil in a Microemulsion for Enhanced Glioblastoma Therapy. ACS Omega. 2026. doi:10.1021/acsomega.6c07252

BibTeX
@article{Guo2026,
  author = {Guo, Xiaoyuan and Jin, Xingxing and Zhang, Zhibo and Liu, Hongmei},
  title = {Nose-to-Brain Co-delivery of Temozolomide and Ganoderma lucidum Spore Oil in a Microemulsion for Enhanced Glioblastoma Therapy},
  journal = {ACS Omega},
  year = {2026},
  doi = {10.1021/acsomega.6c07252}
}
Kostenlos starten →